Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.

Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M.

Cancer Res. 2013 Jan 1;73(1):406-16. doi: 10.1158/0008-5472.CAN-12-1733. Epub 2012 Nov 7.

2.

Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.

Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z.

Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. doi: 10.1016/j.bbrc.2014.01.164. Epub 2014 Feb 3.

PMID:
24502949
3.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

4.
5.

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.

Lundholm L, Hååg P, Zong D, Juntti T, Mörk B, Lewensohn R, Viktorsson K.

Cell Death Dis. 2013 Jan 31;4:e478. doi: 10.1038/cddis.2012.211.

6.

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ.

PLoS One. 2013;8(1):e54193. doi: 10.1371/journal.pone.0054193. Epub 2013 Jan 17.

7.

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

Ma L, Lai D, Liu T, Cheng W, Guo L.

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602. doi: 10.1093/abbs/gmq067. Epub 2010 Aug 12.

PMID:
20705681
8.

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.

Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K.

Cancer Sci. 2013 Jan;104(1):78-84. doi: 10.1111/cas.12045. Epub 2012 Nov 24.

9.

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY.

Oncogene. 2008 Mar 13;27(12):1749-58. Epub 2007 Sep 24.

PMID:
17891174
10.

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.

Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD.

Cancer Res. 2010 Dec 1;70(23):9937-48. doi: 10.1158/0008-5472.CAN-10-0881. Epub 2010 Nov 30.

11.

HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.

Xu Y, Jiang Z, Zhang Z, Sun N, Zhang M, Xie J, Li T, Hou Y, Wu D.

J Cell Biochem. 2014 Jun;115(6):1112-21. doi: 10.1002/jcb.24751.

PMID:
24356998
12.

Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.

Yang JP, Liu Y, Zhong W, Yu D, Wen LJ, Jin CS.

Chin Med J (Engl). 2011 Apr;124(7):1055-60.

13.

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.

Mol Cancer. 2006 Dec 2;5:67.

14.

Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.

Ai Z, Pan H, Suo T, Lv C, Wang Y, Tong S, Liu H.

Cancer Lett. 2011 Nov 28;310(2):181-7. doi: 10.1016/j.canlet.2011.06.035. Epub 2011 Jul 5.

PMID:
21788103
15.

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

16.

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH.

PLoS One. 2008 Jul 9;3(7):e2637. doi: 10.1371/journal.pone.0002637.

17.

Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.

Wang M, Ma X, Wang J, Wang L, Wang Y.

Int J Oncol. 2014 Apr;44(4):1401-9. doi: 10.3892/ijo.2014.2301. Epub 2014 Feb 14.

PMID:
24535252
18.

CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).

Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.

Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.

19.

The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.

Li F, Zeng H, Ying K.

Med Oncol. 2011 Dec;28(4):1458-62. doi: 10.1007/s12032-010-9646-5. Epub 2010 Aug 18.

PMID:
20717756
20.

Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.

Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li Y, Wang F, Song J, Zheng K.

PLoS One. 2012;7(7):e41035. doi: 10.1371/journal.pone.0041035. Epub 2012 Jul 23.

Items per page

Supplemental Content

Write to the Help Desk